INT141184

Context Info Confidence 0.42 First Reported 2007 Last Reported 2010 Negated 0 Speculated 0 Reported most in Body Documents 5 Total Number 7 Disease Relevance 5.48 Pain Relevance 1.15

cytosol (Casp9) peptidase activity (Casp9) mitochondrion (Casp9) nucleus (Casp9) cytoplasm (Casp9)

Anatomy Link Frequency spinal cords 1 neurons 1 Casp9 (Mus musculus)

Pain Link Frequency Relevance Heat Eae 6 99.88 allodynia 1 99.38 Thermal hyperalgesia 1 98.88 Spinal cord 7 91.20 Sciatic nerve 3 87.76 Dorsal horn 2 84.96 Neuropathic pain 4 79.56 Inflammation 23 50.00 dexamethasone 1 31.12 Pain 6 25.00

Disease Link Frequency Relevance Heat Injury 8 99.88 Apoptosis 233 99.70 Neuropathic Pain 5 99.38 Hyperalgesia 1 98.88 Death 67 91.80 Lymphatic System Cancer 287 87.72 Disease 54 75.44 Cancer 54 74.32 Disease Progression 12 65.44 Thymoma 3 62.68

Sentences Mentioned In

Key:

Protein

Mutation

Event

Anatomy

Negation

Speculation

Pain term

Disease term

Administration of phenyl-N-tert-butylnitrone (PBN), a potent ROS scavenger, reduced the development of thermal hyperalgesia and mechanical allodynia at 1 and 3 days post-CCI, and decreased the mRNA levels of bax, apaf-1, and caspase-9.

Negative_regulation (decreased) of caspase-9 associated with allodynia, eae and thermal hyperalgesia

1) Confidence 0.42 Published 2007 Journal Pharmacol. Res. Section Abstract Doc Link 17207636 Disease Relevance 1.42 Pain Relevance 1.15

Besides, a significant inhibition of apoptosis was recorded in the presence of a caspase-9 inhibitor.

Negative_regulation (inhibitor) of caspase-9 associated with apoptosis

2) Confidence 0.17 Published 2010 Journal PLoS ONE Section Body Doc Link PMC3008744 Disease Relevance 1.03 Pain Relevance 0

Guegan et al (2001) illustrated that the protein content of caspase 9 begins to decrease in the spinal cords from symptomatic G93A mice (3 mo of age) compared to nontransgenic control mice and that caspase 9 continues to decrease further in end stage G93A mice (5 mo of age).

Negative_regulation (decrease) of caspase 9 in spinal cords

3) Confidence 0.17 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2827549 Disease Relevance 0.72 Pain Relevance 0

For caspase inhibition assays, Z-IETD-FMK caspase-8 inhibitor or Z-LEHD-FMK caspase-9 inhibitor (Calbiochem) was added one hour prior to addition of Sags.

Negative_regulation (inhibitor) of caspase-9

4) Confidence 0.13 Published 2010 Journal PLoS ONE Section Body Doc Link PMC3008744 Disease Relevance 0.65 Pain Relevance 0

For caspase inhibition assays, Z-IETD-FMK caspase-8 inhibitor or Z-LEHD-FMK caspase-9 inhibitor (Calbiochem) was added one hour prior to addition of Sags.

Negative_regulation (inhibitor) of caspase-9

5) Confidence 0.13 Published 2010 Journal PLoS ONE Section Body Doc Link PMC3008744 Disease Relevance 0.64 Pain Relevance 0

Western blot analysis confirmed the increase of active caspase-3 immunoreactivity and the concomitant decrease of total caspase-9 level in TSM1 (Figure 3C) and primary cultured neurons (Figure 3D and 3E) upon MPP+ treatment.

Negative_regulation (decrease) of caspase-9 in neurons

6) Confidence 0.10 Published 2009 Journal PLoS ONE Section Body Doc Link PMC2675062 Disease Relevance 0.12 Pain Relevance 0

As opposed to other members of the IAP family, XIAP is the only member capable of direct inhibition of both the execution and initiation phases of the apoptotic cascade; it inhibits apoptotic activation by inhibiting caspase-9, and inhibits the execution phase by inhibiting the effector caspases, caspase-3 and caspase-7 [15].

Negative_regulation (inhibiting) of caspase-9 associated with apoptosis

7) Confidence 0.03 Published 2007 Journal J Transl Med Section Body Doc Link PMC1796544 Disease Relevance 0.90 Pain Relevance 0

General Comments

This test has worked.